<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="710">
  <stage>Registered</stage>
  <submitdate>14/09/2005</submitdate>
  <approvaldate>26/09/2005</approvaldate>
  <actrnumber>ACTRN12605000512628</actrnumber>
  <trial_identification>
    <studytitle>Phase 1/2 Pharmacokinetic and Safety Study of Oral Phenoxodiol in Patients with Hormone-Refractory Prostatic Adenocarcinoma</studytitle>
    <scientifictitle>Phase 1/2 Pharmacokinetic and Safety Study of Oral Phenoxodiol in Patients with Hormone-Refractory Prostatic Adenocarcinoma</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Prostatic adenocarcinoma that is refractory to standard therapy including hormonal therapy</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral Phenoxodiol in four dosage cohorts (20mg, 80mg, 200mg and 400mg three times daily).</interventions>
    <comparator />
    <control>Dose comparison</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the pharmacokinetic profile of phenoxodiol when given orally. </outcome>
      <timepoint>Measured at day one of treatment cycle 1.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To determine the safety/tolerability of phenoxodiol when given orally. </outcome>
      <timepoint>Assessed continually throughout the study.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To gain an indication of the anti-tumour activity of phenoxodiol when administered by the oral route.</outcome>
      <timepoint>Anti-tumour activity will be assessed by the fortnightly measurement of PSA levels.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>a) Patients must have histological evidence of prostatic adenocarcinomab) Patients must have a malignancy that, in the opinion of the investigator, has become refractory to standard therapy including hormonal therapy c)Patients must be able to understand the risks and benefits of the study and give written informed consent to participation d) Patients must have an estimated life-expectancy of at least 3 months e) Patients must have -acceptable renal and hepatic function evidenced by a serum creatinine &lt; 0.12mmol/L and serum transaminase levels &lt;3 x the upper limit of normal for the reference laboratory-bilirubin &lt; 20umol/L-adequate haematological function defined by platelets &gt; 100x109/L , WCC &gt; 4x109/L, Hb &gt; 10g/dL, neutrophils &gt; 1.5 x 109 /L f) Patients engaging in sexual activity must (i) agree to use contraception, or (ii) ensure that their sexual partner be using contraception which must be either oral contraceptives, implantable hormonal contraceptives, or double-barrier methods, if of child-bearing potential.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>a) Patients may not be on a concurrent investigational drug study and must be off treatment with any investigational agents for at least 4 weeksb) Patients may not have active infectionc) Patients may not have active CNS metastases.  Patients with known CNS metastases must have received prior radiation therapy, and CNS metastatic disease must be stable for 4 weeks.d) Patients must have recovered from the effects of any prior anti-neoplastic therapy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/10/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Marshall Edwards Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Marshall Edwards Pty Ltd</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Not Applicable</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash Medical Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sue Davies</name>
      <address>Suite 1
10 McCourt Street
Leederville WA 6007</address>
      <phone>+61 8 93822373</phone>
      <fax />
      <email>tulloch@p085.aone.net.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sue Davies</name>
      <address>Suite 1
10 McCourt Street
Leederville WA 6007</address>
      <phone>+61 8 93822373</phone>
      <fax />
      <email>tulloch@p085.aone.net.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>